A multicenter, international, randomized, active comparator-controlled, double-blind, double-dummy, parallel-group, 2-arm, Phase 3 study to compare the efficacy and safety of the oral FXIa inhibitor asundexian (BAY 2433334) with apixaban for the prevention of stroke or systemic embolism in male and female participants aged 18 years and older with atrial fibrillation at risk for stroke.
National Leader: Christopher Hammett
Lead HREC: A/Prof David Colquhoun
Status: Recruiting
No. of Patients Currently Recruited: No. of Patients Required: 511
Participating Australian and New Zealand Sites:
- James Shaw, The Alfred, VIC
- John Amerena, Barwon Health, Geelong, VIC
- Tim Kleinig, Royal Adelaide Hospital, SA
- Atifur Rahman, Gold Coast University Hospital, QLD
- Dennis Cordato, Liverpool Hospital, NSW
- Gary Gan, Blacktown Hospital, NSW
- Rohan Poulter, Sunshine Coast University Hospital, QLD
- Bruce Campbell, Royal Melbourne Hospital, VIC
- Philip Choi, Box Hill Hospital, VIC
- Astin Lee, Wollongong Hospital, NSW
- Anandroop Lahiri, Flinders Med Centre, SA
- David Cross, GenesisCare, QLD
- Peter Blombery, The Avenue Cardiovascular, VIC
- Scott McKenzie, The Prince Charles Hospital, QLD
- Christopher Hammett, Royal Brisbane and Women’s Hospital, QLD
- Carlos Garcia Esperon, John Hunter Hospital, NSW
- Ernesto Oqueli, Grampians Health, Ballarat VIC
- Jamie Morton, GenesisCare Leabrook, SA
- Peter Purnell, GenesisCare Joondalup, WA
- Patrick Carroll, Redcliffe Hospital, QLD
- Darshan Ghia, Fiona Stanley Hospital, WA
- David Colquhoun, Core Research Group Pty Ltd, QLD
- David Eccleston, GenesisCare, VIC
- Walter Abhayaratna, The Canberra Hospital, ACT
- David Brieger, Concord Repatriation General Hospital, NSW
- Clara Chow, Westmead Hospital, NSW
- Faraz Pathan, Nepean Hospital, NSW
- Rajiv Mahajan, Lyell McEwin Hospital, SA
- Andrew Hamilton, Nightingale Cardiology, SA
- Christopher Zeitz, Queen Elizabeth Hospital, SA
- Deepak Haikerwal, HeartWest and Baker HDI, VIC
- Swati Mukherjee, Cabrini, VIC
